ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis bags rights to Galapagos/MorphoSys atopic dermatitis drug
July 20, 2018Novartis has signed an exclusive global license agreement with Galapagos and MorphoSys for MOR106, a novel antibody directed against IL-17C. -
Atopic dermatitis patients to be denied NHS access to Dupixent
July 19, 2018The National Institute for Health and Care Excellence has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis. -
Lilly/Incyte's baricitinib musters mixed data in atopic dermatitis trial
September 18, 2017In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective, prompting unfavorable comparisons with Sanofi and Regeneron's recently approved Dupixent.
Pharma Sources Insight January 2025
